INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Overview of Lapatinib: Chemistry, Pharmacology, and Clinical Applications

Akash Darekar*, Dr. V. M Satpute, Ghodake S. R.

Loknete Shri Dadapatil Pharate Collage of Pharmacy Mandavgaon Pharata Tal. Shirur Dist. Pune.

ARTICLE INFO

Published: 22 May 2025
Keywords:
Lapatinib: Chemistry, Pharmacology, and Clinical Applications, selectivity, linearity, accuracy, precision, recovery, matrix effect, and stability
DOI:
10.5281/zenodo.15489237

ABSTRACT

The present study focuses on the development and validation of a sensitive, accurate, and reproducible bioanalytical method for the estimation of Lapatinib in active pharmaceutical ingredient (API) form and marketed formulations using human plasma. Lapatinib, a dual tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, requires precise quantification in biological matrices for effective pharmacokinetic and bioequivalence studies. A high-performance liquid chromatography (HPLC) method coupled with UV detection was developed for the extraction and quantification of Lapatinib from plasma samples. The method was optimized using appropriate sample preparation techniques, including protein precipitation, to ensure high recovery and minimal matrix interference. Method validation was carried out in accordance with USFDA and ICH guidelines, evaluating parameters such as selectivity, linearity, accuracy, precision, recovery, matrix effect, and stability under various conditions. The developed method demonstrated excellent linearity over a concentration range suitable for pharmacokinetic studies, with correlation coefficients (R^2) consistently greater than 0.998. Accuracy and precision were within acceptable limits, with %RSD less than 15%. The method proved robust, sensitive, and specific, making it suitable for routine analysis of Lapatinib in clinical and regulatory settings. This validated method can be effectively applied for bioavailability and bioequivalence studies, as well as for therapeutic drug monitoring in clinical research.

INTRODUCTION

Lapatinib is a potent, orally active, dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), both of which are overexpressed in certain types of breast cancer. It is widely prescribed in combination therapy for HER2-positive metastatic breast

***Corresponding Author:** Akash Darekar
Address: *Loknete Shri Dadapatil Pharate Collage of Pharmacy Mandavgaon Pharata Tal. Shirur Dist. Pune.*
Email ✉: navnathkharat678@email.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

cancer, particularly in patients who have progressed on prior therapies. Given its narrow therapeutic window and the potential for interindividual variability in pharmacokinetics, accurate quantification of Lapatinib in biological matrices such as human plasma is essential for therapeutic drug monitoring, pharmacokinetic profiling, and bioequivalence studies. Bioanalytical method development plays a pivotal role in the drug development process by ensuring reliable quantification of active pharmaceutical ingredients (APIs) in various biological matrices. A validated method must meet stringent criteria for accuracy, precision, selectivity, sensitivity, and stability, as outlined by regulatory agencies such as the US Food and Drug Administration (FDA) and International Council for Harmonisation (ICH).Although several analytical methods have been reported for the estimation of Lapatinib in pharmaceutical formulations and biological fluids, many of them involve complex sample preparation techniques or lack adequate sensitivity and reproducibility. Therefore, there is a need for a simple, efficient, and highly sensitive bioanalytical method for the estimation of Lapatinib in human plasma, which can be effectively applied in routine quality control and clinical studies.The present study aims to develop and validate a reliable high-performance liquid chromatography (HPLC) method for the estimation of Lapatinib in both API and marketed formulations using human plasma. The method is designed to be sensitive, reproducible, and in compliance with regulatory validation guidelines, ensuring its suitability for clinical and bioanalytical applications

Introduction to Bioanalytical Methods

Bioanalytical methods are essential tools in the pharmaceutical and clinical research fields for the quantitative determination of drugs and their metabolites in biological matrices such as plasma, serum, blood, urine, and tissues. These methods play a critical role in the drug development process, supporting pharmacokinetic, bioavailability, bioequivalence, and toxicokinetic studies. Accurate and reliable bioanalytical methods are crucial for generating data that determine the efficacy, safety, and dosage of therapeutic agents. The development of a bioanalytical method involves selecting an appropriate analytical technique, optimizing sample preparation protocols, and ensuring the method is robust, sensitive, and specific to the analyte of interest. Techniques such as high-performance liquid chromatography (HPLC), liquid chromatography–mass spectrometry (LC-MS), and gas chromatography (GC) are widely used depending on the nature and sensitivity requirements of the drug. Validation of bioanalytical methods is mandated by regulatory authorities such as the US Food and Drug Administration (FDA) and International Council for Harmonizations (ICH) to ensure the reliability and reproducibility of results. Key validation parameters include selectivity, accuracy, precision, linearity, limit of detection (LOD), limit of quantification (LOQ), recovery, matrix effect, and stability under various conditions. In the context of cancer therapeutics like Lapatinib, a validated bioanalytical method allows for accurate quantification in human plasma, enabling effective therapeutic drug monitoring and facilitating pharmacokinetic evaluations critical to clinical success.

Drug Profile of Lapatinib

Lapatinib is a synthetic, orally active 4-anilinoquinazoline derivative classified as a dual tyrosine kinase inhibitor. It is chemically designed to target and inhibit the ATP-binding domains of EGFR (ErbB1) and HER2 (ErbB2) receptors.

Generic Name: Lapatinib

Chemical Name: N-[3-chloro-4-[(3-fluorobenzyl) oxy] phenyl]-6- [5-({[2-

(methanesulfonyl)ethyl] amino} methyl)-2-furyl]-4-quinazolinamine

Molecular Formula: C29H26ClFN4O4S

Molecular Weight: 581.05 g/mol

Drug Class: Tyrosine kinase inhibitor (TKI)
Therapeutic Category: Antineoplastic agent

solubility:

- **Freely soluble in DMSO**
- **Slightly soluble in water**
- Solubility is enhanced in acidic media and improved in salt form (commonly used as Lapatinib Ditosylate in formulations)

pKa Values:

- pKa ~ 7.2 (basic amine group

Structure-



Available Forms of Lapatinib

Lapatinib is available primarily in the **oral solid dosage form**, specifically designed for ease of administration and systemic absorption. Below are the commonly available forms:

Tablet Form (Oral Use)

- **Brand Name:** *Tykerb* (by GlaxoSmithKline) / *Tyverb* (in some international markets)
- **Generic Name:** Lapatinib Ditosylate
- **Strength:** 250 mg
- **Formulation:** Film-coated tablets
- **Administration Route:** Oral
- **Packaging:** Blister packs or HDPE bottles (varies by brand and region)
- **Salt Form Used in Formulations**

 Lapatinib Ditosylate Monohydrate is the commonly used salt form in pharmaceutical preparations due to improved stability and solubility.

Mechanism of Action

Lapatinib is a reversible dual tyrosine kinase inhibitor that selectively targets the intracellular domains of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). By inhibiting the autophosphorylation of these receptors, Lapatinib blocks downstream signaling pathways involved in cell proliferation and survival, particularly in HER2overexpressing breast cancer cells. Lapatinib is a small molecule, reversible tyrosine kinase inhibitor (TKI) that selectively targets two key members of the ErbB receptor family:

- Epidermal Growth Factor Receptor (EGFR, also known as ErbB1)
- Human Epidermal Growth Factor Receptor 2 (HER2/neu, or ErbB2)

Lapatinib binds to the intracellular ATP-binding site of these receptors, thereby inhibiting their kinase activity. This prevents autophosphorylation of the receptors and blocks downstream signaling pathways, particularly the:

- RAS/RAF/MEK/ERK (MAPK) pathway – involved in cell proliferation

- PI3K/AKT pathway – involved in cell survival and anti-apoptosis

By inhibiting both EGFR and HER2 pathways, Lapatinib suppresses tumor cell growth, proliferation, and survival, especially in HER2-overexpressing breast cancer cells. Unlike monoclonal antibodies like trastuzumab, which target extracellular domains, Lapatinib acts on the intracellular domain, making it effective even in some trastuzumab-resistant tumors.

Structure–Activity Relationship (SAR) of Lapatinib

Lapatinib is a 4-anilinoquinazoline derivative that exhibits potent dual inhibition of EGFR (ErbB1) and HER2 (ErbB2) tyrosine kinases. Its structure–activity relationship is centered around the quinazoline core, various substituted aryl groups, and side chains that are essential for its kinase selectivity and potency.

Key Structural Features and Their Roles:

Quinazoline Core (4-anilinoquinazoline):

- Acts as the **ATP mimetic scaffold** that binds to the ATP-binding site of EGFR/HER2.
- Essential for competitive inhibition of tyrosine kinase activity.

3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl Moiety (at the 4-aniline position):

- Enhances selectivity and affinity for both EGFR and HER2.
- The fluorobenzyl ether contributes to hydrophobic interactions within the binding pocket.

Substitution at Position 6 of the Quinazoline Ring (furylmethylamine side chain): o This polar, flexible chain increases **water solubility** and **binding strength** via hydrogen bonding.

- Contributes to inhibition of HER2 more selectively over other kinases.

Methanesulfonyl-ethylamine Group:

- Improves pharmacokinetic properties such as solubility and metabolic stability.
- Also contributes to bioavailability and oral efficacy.

Reversible Binding Nature:

- Lapatinib does not form covalent bonds with the kinase domain, enabling **reversible inhibition**, which may reduce off-target toxicity compared to irreversible inhibitors.

SAR Summary Table

Structural Feature	Function / Importance
Quinazoline core	ATP-site mimic; key to EGFR/HER2 kinase inhibition
3-chloro-4-(3- fluorobenzyl)oxyphenyl group	Enhances selectivity and binding affinity
Furylmethylamine side chain	Increases HER2 inhibition and solubility
Methanesulfonyl-ethylamine	Improves pharmacokinetics and solubility
Reversible binding	Reduces permanent off-target effects

Indications:

- HER2-positive metastatic breast cancer (in combination with capecitabine or letrozole)
- Investigational uses in other solid tumors expressing EGFR or HER2

Pharmacokinetics of Lapatinib

Lapatinib exhibits complex pharmacokinetic behavior characterized by variable absorption, extensive metabolism, and primarily biliary excretion. The pharmacokinetics of Lapatinib are nonlinear over the therapeutic dose range and are influenced by food intake, hepatic function, and co-administered drugs.

1. Absorption

- **Bioavailability:** Low and variable; significantly affected by food.
- **Food Effect:** High-fat meals increase systemic exposure by approximately 3–4 fold.
- **Time to Peak Concentration (Tmax):** Typically 4 to 6 hours after oral administration.

2. Distribution

- **Volume of Distribution (Vd):** High (>1000 L), indicating extensive tissue distribution.
- **Plasma Protein Binding:** >99%, primarily bound to albumin and alpha1-acid glycoprotein.
- **Crosses Blood-Brain Barrier:** Limited, but may still have CNS activity.

3. Metabolism

- **Primary Site:** Liver
- **Enzymes Involved:** Mainly metabolized by **CYP3A4** and **CYP3A5**; minor metabolism by CYP2C19 and CYP2C8.
- **Metabolites:** Several inactive oxidative metabolites.

4. Elimination

- **Major Route:** Fecal excretion via the hepatobiliary system.
- **Renal Excretion:** Minimal (<2% of the dose).
- **Elimination Half-Life (t½):** Approximately 24 hours.
- **Clearance:** Hepatic; affected in patients with impaired liver function.

5. Accumulation

- Reaches steady-state concentrations in about 6–7 days of once-daily dosing.
- Accumulates with repeated dosing due to long half-life and high tissue distribution.

6. Drug Interactions

- Lapatinib is a substrate of CYP3A4/5, and its plasma concentration may be increased by inhibitors (e.g., ketoconazole) or decreased by inducers (e.g., rifampin).
- It also inhibits P-glycoprotein (P-gp), potentially affecting the disposition of other drugs.

Pharmacodynamics of Lapatinib

Lapatinib is an orally active, small molecule dual tyrosine kinase inhibitor that exerts its pharmacological action by targeting epidermal growth factor receptor (EGFR or ErbB1) and human epidermal growth factor receptor 2 (HER2 or ErbB2).

Mechanism of Pharmacodynamic Action:

- Lapatinib competitively binds to the ATP-binding site on the intracellular domain of EGFR and HER2.
- This inhibits receptor autophosphorylation, which in turn blocks downstream signaling pathways, particularly:
- **MAPK/ERK pathway** – associated with cell proliferation.
- **PI3K/AKT pathway** – associated with cell survival and antiapoptosis.
- Inhibition of these pathways leads to cell cycle arrest and apoptosis in cancer cells that are

dependent on EGFR or HER2 signaling for growth and survival.

Therapeutic Effect:

- Lapatinib is particularly effective in HER2-overexpressing breast cancer and shows clinical benefit in patients who have progressed on trastuzumab.
- It is used either alone or in combination with other chemotherapeutic agents such as capecitabine or letrozole to enhance efficacy.

Onset and Duration:

- Pharmacodynamic effects (e.g., reduction in tumor cell proliferation markers) are seen within a few days of therapy, but clinical effects (e.g., tumor shrinkage) typically take several weeks.
- Continuous daily dosing is required to maintain receptor inhibition due to its reversible binding nature.

Biomarkers and Target Engagement:

- Lapatinib efficacy is often evaluated through biomarkers such as:
- Reduced phosphorylation of HER2 and EGFR o Decreased levels of Ki-67 (proliferation marker) o Changes in circulating tumor DNA (ctDNA)

Resistance Mechanisms:

- Resistance may develop via: o Activation of alternative growth pathways (e.g., IGF-1R) o HER2 mutations
- Compensatory upregulation of other ErbB receptors o Incomplete inhibition due to limited penetration in some tumor sites (e.g., CNS)

Adverse Effects of Lapatinib

Lapatinib, like other tyrosine kinase inhibitors (TKIs), is associated with a range of adverse effects, which can vary in severity and frequency depending on the dosage, duration of therapy, and combination with other anticancer agents. Most adverse effects are manageable, but some may require dose adjustment or treatment interruption.

Common Adverse Effects (≥10% of patients):

Gastrointestinal:

Diarrhea (most common, may be severe) o Nausea and vomiting o Loss of appetite o Stomatitis or oral mucositis

Dermatologic:

o Rash (acneiform, EGFR-related)

o Dry skin

Pruritus (itching)

General:

o Fatigue o Headache o Pain (back or extremity)

Less Common but Clinically Significant Adverse Effects (<10%):

Hepatotoxicity:

- Elevated liver enzymes (ALT, AST)
- Rare cases of severe liver injury, including fatal hepatotoxicity
- Regular liver function monitoring is advised

Cardiac Toxicity:

Decreased left ventricular ejection fraction (LVEF)

o Risk is higher when combined with other cardiotoxic agents like trastuzumab

Pulmonary Toxicity:

o Interstitial lung disease and pneumonitis (rare)

QT Prolongation:

Potential risk for cardiac arrhythmias, especially when used with other QT-prolonging drugs

Hand-foot syndrome:

o Particularly when combined with capecitabine

Hematologic Effects:

- Neutropenia
- Anemia (less frequent compared to cytotoxic chemotherapies)

Hypersensitivity Reactions:

Rare cases of angioedema and anaphylaxis have been reported

Risk in Special Populations:

Pregnancy Category D: Teratogenic and should not be used in pregnancy.

Hepatic Impairment: Increased risk of toxicity due to hepatic metabolism.

Monitoring Parameters:

- Liver function tests (baseline and periodically)
- Cardiac function (especially in patients with pre-existing heart disease)
- ECG (for QT interval)
- Patient hydration and electrolytes (for diarrhea management)

Management of Adverse Effects:

- **Dose modification** or temporary discontinuation may be necessary.
- **Antidiarrheal agents** (e.g., loperamide) for GI toxicity.
- **Topical or systemic corticosteroids** for rash.

Supportive care for fatigue and mucositis.

Drug Interactions of Lapatinib

Lapatinib, a dual tyrosine kinase inhibitor targeting EGFR and HER2, is extensively metabolized by the CYP3A4/5 enzyme system and can interact with various drugs, potentially altering its pharmacokinetics and increasing the risk of toxicity or reduced efficacy.

1. Enzyme-Mediated Interactions

A. CYP3A4 Inhibitors – Increase Lapatinib Levels

Co-administration with strong CYP3A4 inhibitors can increase lapatinib plasma concentration, raising the risk of toxicity (e.g., diarrhea, hepatotoxicity, QT prolongation).

Examples:

- Ketoconazole
- Itraconazole
- Clarithromycin
- Ritonavir
- Grapefruit juice (also inhibits CYP3A4)

Recommendation:

Dose adjustment or close monitoring may be necessary.

B. CYP3A4 Inducers – Decrease Lapatinib Levels

Inducers can reduce lapatinib plasma concentration, potentially reducing therapeutic effectiveness.

Examples:

- Rifampin
- Carbamazepine
- Phenytoin

- St. John's Wort

Recommendation:

Avoid co-administration or increase lapatinib dose cautiously with monitoring.

P-Glycoprotein (P-gp) Substrate/Modulator

Lapatinib is a substrate and inhibitor of P-gp, which affects the absorption and distribution of other drugs.

Interactions with:

- Digoxin (may increase digoxin levels)
- Dabigatran and other oral anticoagulants (due to P-gp modulation)

Recommendation:

Monitor closely for signs of toxicity of co-administered P-gp substrates.

QT-Prolonging Agents

Lapatinib may prolong QT interval, and concurrent use with other QT prolonging drugs may increase the risk of cardiac arrhythmias.

Examples:

- Amiodarone
- Sotalol
- Ciprofloxacin
- Haloperidol

Contraindications of Lapatinib

Lapatinib is generally well-tolerated under proper clinical supervision, but there are specific situations in which its use is contraindicated due to the potential for serious adverse effects or lack of benefit.

1. Hypersensitivity

Absolute Contraindication

- Lapatinib is contraindicated in patients with a known hypersensitivity to Lapatinib or any of its formulation components (e.g., ditosylate salt).
- May lead to severe allergic reactions such as anaphylaxis, angioedema, or severe dermatologic reactions.

2. Severe Hepatic Impairment

- Use is contraindicated or not recommended in patients with severe liver dysfunction (Child-Pugh Class C).
- Lapatinib is extensively metabolized in the liver, and impaired clearance can increase systemic exposure, leading to hepatotoxicity.

3. Pregnancy and Lactation

Contraindicated in Pregnancy (Category D)

o Lapatinib may cause fetal harm, including developmental toxicity and teratogenic effects.

Breastfeeding is not recommended

o Risk of serious adverse effects in the infant due to unknown excretion in human milk.

4. QT Prolongation Risk

Contraindicated in patients with:

Congenital long QT syndrome

- Uncontrolled electrolyte imbalances (e.g., hypokalemia, hypomagnesemia)
- Concurrent use of multiple QT-prolonging drugs
- Increases risk of life-threatening arrhythmias (e.g., Torsades de Pointes).

5. Co-administration with Strong CYP3A4 Modulators

- Not absolutely contraindicated, but should be avoided if strong CYP3A4 inducers (e.g., rifampin, phenytoin) or inhibitors (e.g., ketoconazole) cannot be managed or adjusted.
- Can significantly alter plasma concentrations, leading to ineffectiveness or toxicity.

Clinical Considerations:

- Baseline liver function and ECG should be assessed prior to initiation.
- Use caution in patients with a history of cardiac disease, hepatic dysfunction, or electrolyte imbalance.

Toxicity of Lapatinib

Toxicity Summary Table

System Affected	Toxic Effect	Monitoring
Liver	Hepatotoxicity	LFTs regularly
Cardiac	↓ LVEF, QT prolongation	ECG, echocardiogram
GI	Diarrhea, nausea, dehydration	Fluid/electrolyte balance
Skin	Rash, hand-foot syndrome	Visual exam, dermatologic care
Reproductive	Teratogenicity, infertility risk	Avoid during pregnancy
General	Fatigue, mucositis	Clinical assessment

Common Brand Names of Lapatinib

Tykerb®

- **Manufacturer:** Novartis (originally by GlaxoSmithKline)
- **Formulation:** Lapatinib Ditosylate tablets
- **Strengths:** 250 mg
- **Indication:** HER2-positive advanced or metastatic breast cancer, usually in combination with capecitabine or letrozole

Tyverb®

o **Marketed in Europe, Asia, and other regions** (same as Tykerb in the US)

- **Manufacturer:** Novartis
- **Formulation & Indications:** Same as Tykerb
- **Lapahope®**
- **Manufacturer:** Hetero Labs Ltd (India) o **Strengths:** 250 mg
- **Generic formulation of Lapatinib**

Lapatinib Natco®

o **Manufacturer:** Natco Pharma Ltd (India)

o **Used in generic markets, particularly in India and developing countries**

Lapatib®

o **Manufacturer:** Cipla Ltd (India)

o **Available in 250 mg tablets**

Uses of Lapatinib

Lapatinib is a dual tyrosine kinase inhibitor that blocks both the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2/neu). It is primarily used in the treatment of HER2positive breast cancer, often in advanced or metastatic stages.

1. Advanced or Metastatic Breast Cancer (HER2-positive)

A. In Combination with Capecitabine

For patients with HER2-positive metastatic breast cancer who have progressed on prior therapies including:

o Anthracyclines

o Taxanes

o Trastuzumab (Herceptin)

- Lapatinib + Capecitabine has shown improved progression-free survival.

B. In Combination with Letrozole

- For postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer.
- Used as a first-line therapy in patients unsuitable for chemotherapy.
- Mechanism: Letrozole inhibits estrogen synthesis, while Lapatinib blocks HER2 signaling.

2. Potential Off-Label or Investigational Uses

Though not FDA-approved for the following, Lapatinib has been studied in:

HER2-positive gastric cancer

Non-small cell lung cancer (NSCLC) with EGFR or HER2 mutations

 Head and neck cancers

Brain metastases from HER2-positive breast cancer (due to its ability to cross the blood-brain barrier)

HER2-positive colorectal cancer

CONCLUSION

Lapatinib is a potent, orally active dual tyrosine kinase inhibitor that has significantly contributed to the treatment of HER2-positive breast cancer, especially in patients with advanced or metastatic disease. Its ability to inhibit both HER2 (ErbB2) and EGFR (ErbB1) pathways offers a strategic advantage in targeting cancer cell proliferation and survival mechanisms. The comprehensive review of Lapatinib's chemical profile, pharmacokinetics, pharmacodynamics, mechanism of action, and clinical utility highlights its relevance in targeted cancer therapy. Despite its promising therapeutic effects, attention to adverse effects, drug interactions, and resistance mechanisms is essential for optimizing patient outcomes. Continuous research into derivatives, combination therapies, and nanotechnology-based delivery systems may enhance its clinical efficacy and overcome existing limitations.Overall, Lapatinib remains a valuable agent in oncology, and ongoing innovations may expand its applications in personalized and precision medicine.

REFERENCES

1. Atalay G, Cardoso F, Awada A, Piccart MJ (2003) Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 14:1346–1363
2. Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, Smith DA, Koch KM, Stead AG, Mangum S, Bowen CJ, Spector NL, Hsieh S, Adams VR (2005) Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23:39–49
3. Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L (2007) Lapatinib in breast cancer. Ann Oncol 18(Suppl 6):26–30
4. Blackwell KL, Burstein H, Pegram M, Storniolo AM, Salazar VM, Maleski JE, Lin X, Spector N, Stein SH, Berger MS (2005) Determining relevant biomarkers from tissue

and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 23:3004

5. Blackwell KL, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen MJ, Berger MS (2004) A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 22:3006
6. Burris HA 3rd (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(Suppl 3):10–15
7. Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305–5313
8. Burstein H, Storniolo AM, Franco S, Salazar VM, Sorensen MJ, Stein SH (2004) A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Annal Oncol 15:1040
9. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543
10. Cappuzzo F, Toschi L, Finocchiaro G, Ligorio C, Santoro A (2007) Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. Int J Biol Markers 22: S10–S23
11. Chu Q, Goldstein L, Murray N, Rowinsky E, Cianfrocca M, Gale M, Ho P, Paul E, Loftiss J, Pandite L (2005) A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. J Clin Oncol 23:3001
12. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516
13. Danielsen AJ, Maihle NJ (2002) The EGF/ErbB receptor family and apoptosis. Growth Factors 20:1–15
14. De Bono JS, Schwartz G, Monroe P (2003) Phase I and pharmacokinetics (PK) study of oral GW572016, a potent reversible dual inhibitor of both erbB1 and erbB2 tyrosine kinase (TK), administered in combination with cepecitabine. Proc Am Soc Clin Oncol 22:981a
15. Dees EC, Burris H, Hurwitz H, Dowlati A, Smith D, Koch K, Stead A, Mangum S, Harris J, Spector N (2004) Clinical summary of 67 heavily pretreated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. J Clin Oncol 22:3188
16. DeSimone PA, Bence AK, Anderson EB, Halepota MA, Smith DA, Koch KM, Stead AG, Mangum SG, Spector NL, Davis GA, Doukas MA, Adams VR (2002) A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc Am Soc Clin Oncol 21:375

17. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544–5552
18. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006a) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743
19. Geyer CE, Forster JK, Cameron D (2006b) A phase III, randomized, openlabel, international study comparing lapatinib and capecitabine vs capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). J Clin Oncol 24:3717–3718
20. Gomez HL, Chavez MA, Doval DC, Chow LWC, Wood BA, Berger MS, Sledge GW (2005) A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 23:3046
21. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999–3005
22. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655
23. Gridelli C, Rossi A, Maione P, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Palazzolo G, Falanga M, Colantuoni G (2008) New insights in drug development for the non-small cell lung cancer therapy. Front Biosci 13:5108–5119
24. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092–1103
25. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2006) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295–300
26. Johnston S, Pegram M, Press M, Pippen J, Pivot X, Gomez H, Florance A, O'Rourke L, Maltzman J, (2008) Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. San Antonio Breast Cancer Symposium (abstract)
27. Johnston SR (2005) Clinical trials of intracellular signal transductions inhibitors for breast cancer–a strategy to overcome endocrine resistance. Endocr Relat Cancer 12(Suppl 1): S145–S157
28. Jones SF, Hainsworth JD, Spigel DR, Peacock NW, Willcutt NT, Pandite LN, Versola MJ, Koch KM, Greco F, Burris HA (2004) A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J Clin Oncol 22:2083
29. Kaufman B, Trudeau ME, Johnston S, Awada A, Blackwell KL, Bachelot T, Salazar V,

Westlund R, Desilvio M, Zaks T (2008) Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009. J Clin Oncol 26:636

30. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY, Bang YJ (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272:296–306
31. Klapper LN, Kirschbaum MH, Sela M, Yarden Y (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25–79
32. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumabtreated breast cancer cells. Cancer Res 66:1630–1639
33. Lakhai WS, Beijnen JH, Den Boer SS, Westermann AM, Versola M, Koch K, Ho P, Pandite L, Richel DJ, Schellens J (2004) Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. J Clin Oncol 22:2044
34. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993–1999
35. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Laessig D, Roché H, Zembryki D, Oliva CR, Winer EP (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 25:1012
36. Lin NU, Winer EP (2004) New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 6:204–210
37. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A (2006) Trastuzmab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio breast cancer conference 2006 (abstract 3)
38. Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30:1426–1447
39. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787– 2799
40. Midgley R, Flaherty KT, Haller DG, Versola MJ, Smith DA, Koch KM, Pandite L, Kerr DJ, O'Dwyer PJ, Middelton MR (2005) Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV). J Clin Oncol 23:3086
41. Milanezi F, Carvalho S, Schmitt FC (2008) EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 8:417–434
42. Minami H, Nakagawa K, Kawada K, Mukai H, Tahara M, Kurata T, Uejima H, Nogami T, Sasaki Y, Fukuoka M (2004) A phase I study

of GW572016 in patients with solid tumors. J Clin Oncol 22:3048

43. Montemurro F, Valabrega G, Aglietta M (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7:257– 268
44. Moy B, Goss PE (2006) Lapatinib: current status and future directions in breast cancer. Oncologist 11:1047–1057
45. Moy B, Goss PE (2007a) Lapatinib-associated toxicity and practical management recommendations. Oncologist 12:756–765
46. Moy B, Goss PE (2007b) TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 7: 489–492
47. Nahleh ZA (2008) Molecularly targeted therapy in breast cancer: the new generation. Recent Patents Anticancer Drug Discov 3:100–104
48. Nahta R, Hortobagyi GN, Esteva FJ (2003) Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8:5–17
49. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280
50. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40:261–269
51. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26:1015
52. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H (2000) Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275: 30934–30942
53. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167.

HOW TO CITE: Akash Darekar*, Dr. V. M Satpute, Ghodake S. R., Overview of Lapatinib: Chemistry, Pharmacology, and Clinical Applications, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 5, 3774-3787. https://doi.org/10.5281/zenodo.15489237